PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What does treatment of hepatitis C currently center around?

ANSWER

Treatment now centers around direct acting antiviral drugs (DAAs). These medicines are highly effective for most people with hepatitis C and are interferon-free and often ribavirin-free. This means they typically have fewer side effects. The treatments are often simpler -- consisting of fewer pills for a shorter amount of time. DAAs are available as either single drugs or combined with other medicines in one pill. Elbasvir-grazoprevir (Zepatier), ledipasvir-sofosbuvir (Harvoni), and sofosbuvir-velpatasvir (Epclusa) are once daily combination pills. Depending on the type of hepatitis C infection, these can often cure the disease in eight to 12 weeks. Other treatment options include: daclatasvir (Daklinza); ombitasvir-paritaprevir-ritonavir plus dasabuvir (Viekira Pak, Viekira XR); ombitasvir-paritaprevir-ritonavir (Technivie); or some combinations of simeprevir (Olysio); sofosbuvir (Sovaldi); peginterferon or ribavirin. Ask your doctor what's best for you, based on your medical needs. All these drugs are quite expensive, so check with your insurance company or ask your doctor about any drug company assistance programs.

From: Chronic Hepatitis C: The Basics WebMD Medical Reference

SOURCES:

FDA. News releases. "FDA approves Mavyret for Hepatitis C." 

National Digestive Diseases Information Clearinghouse: "Chronic Hepatitis C: Current Disease Management," "What I need to know about Hepatitis C."

U.S. Department of Veterans Affairs: "Hepatitis C Basics."

CDC: "Hepatitis C Information for the Public."

MedlinePlus, U.S. National Library of Medicine: "U.S. hepatitis C cases down sharply since 1980s."

Paul Gaglio, MD, medical director of liver transplantation, division of hepatology at Montefiore Medical Center.

U.S. Department of Veterans Affairs: "Hepatitis C Treatment Side Effects Management Chart."

UptoDate: "Patient Information: "Hepatitis C (Beyond the Basics)."

News release, FDA.

 

Reviewed by Melinda Ratini on September 10, 2017

SOURCES:

FDA. News releases. "FDA approves Mavyret for Hepatitis C." 

National Digestive Diseases Information Clearinghouse: "Chronic Hepatitis C: Current Disease Management," "What I need to know about Hepatitis C."

U.S. Department of Veterans Affairs: "Hepatitis C Basics."

CDC: "Hepatitis C Information for the Public."

MedlinePlus, U.S. National Library of Medicine: "U.S. hepatitis C cases down sharply since 1980s."

Paul Gaglio, MD, medical director of liver transplantation, division of hepatology at Montefiore Medical Center.

U.S. Department of Veterans Affairs: "Hepatitis C Treatment Side Effects Management Chart."

UptoDate: "Patient Information: "Hepatitis C (Beyond the Basics)."

News release, FDA.

 

Reviewed by Melinda Ratini on September 10, 2017

NEXT QUESTION:

What is the outlook for patients with hepatitis B?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.